Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies

被引:125
作者
Vera-Llonch, Montserrat
Oster, Gerry
Ford, Colleen M.
Lu, John
Sonis, Stephen
机构
[1] Policy Anal Inc, Brookline, MA 02445 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Amgen Inc, Thousand Oaks, CA 91320 USA
关键词
oral mucositis; allogeneic; hematopoietic stem-cell transplantation; costs; outcomes;
D O I
10.1007/s00520-006-0176-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Goals of the work: To assess the relationship between oral mucositis (OM) and adverse clinical and economic outcomes in patients with hematologic malignancies receiving allogeneic hematopoietic stem-cell transplantation (HSCT). Materials and methods: A retrospective chart review study of 281 allogeneic HSCT recipients with hematologic malignancies was undertaken at a single academic center. OM extent and severity were assessed across eight oropharyngeal sites using a validated scale, which was scored as follows: no erythema/ ulceration= 0; erythema only= I; ulceration, one site= II; ulceration, two sites= III; ulceration, three sites= IV and ulceration, four or more sites= V. OM assessments began on the day of conditioning and continued twice weekly within 28 days or hospital discharge. Analyses examined the relationship between the worst OM grade and selected adverse outcomes, including days with fever, days of total parenteral nutrition (TPN), days of parenteral narcotic therapy, incidence of significant ( common terminology criteria (CTC) grade 3 or 4) infection, mortality and inpatient days and charges. Main results: The mean age of the study subjects was 41 years. Of the patients, 96% (n= 269) received total body irradiation and 76% ( n= 214) experienced an OM grade of >= II (i.e., ulceration). The worst OM grade was significantly ( p < 0.05) associated with the number of days of TPN and parenteral narcotic therapy, number of days with fever, incidence of significant infection, time in hospital and total inpatient charges. Conclusions: OM is associated with worse clinical and economic outcomes in patients with hematologic malignancies undergoing allogeneic HSCT.
引用
收藏
页码:491 / 496
页数:6
相关论文
共 16 条
[1]
Bellm LA, 2000, SUPPORT CARE CANCER, V8, P33
[2]
Mucositis after allogeneic hematopoietic stem cell transplantation: A cohort study of methotrexate- and non-methotrexate-containing Graft-versus-host disease prophylaxis regimens [J].
Cutler, C ;
Li, SL ;
Kim, HT ;
Laglenne, P ;
Szeto, KC ;
Hoffmeister, L ;
Harrison, MJ ;
Ho, V ;
Alyea, E ;
Lee, SJ ;
Soiffer, R ;
Sonis, S ;
Antin, JH .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (05) :383-388
[3]
The burdens of cancer therapy - Clinical and economic outcomes of chemotherapy-induced mucositis [J].
Elting, LS ;
Cooksley, C ;
Chambers, M ;
Cantor, SB .
CANCER, 2003, 98 (07) :1531-1539
[4]
A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation [J].
Hwang, WYK ;
Koh, LP ;
Ng, HJ ;
Tan, PHC ;
Chuah, CTH ;
Fook, SC ;
Chow, H ;
Tan, KW ;
Wong, C ;
Tan, CH ;
Goh, YT .
BONE MARROW TRANSPLANTATION, 2004, 34 (01) :51-56
[5]
McGuire D B, 1993, Oncol Nurs Forum, V20, P1493
[6]
MONOPOLI M, 1991, P ANN M SOC OR ONC
[7]
Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants [J].
Rapoport, AP ;
Watelet, LFM ;
Linder, T ;
Eberly, S ;
Raubertas, RF ;
Lipp, J ;
Duerst, R ;
Abboud, CN ;
Constine, L ;
Andrews, J ;
Etter, MA ;
Spear, L ;
Powley, E ;
Packman, CH ;
Rowe, JM ;
Schwertschlag, U ;
Bedrosian, C ;
Liesveld, JL .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2446-2453
[8]
Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia [J].
Robien, K ;
Schubert, MM ;
Bruemmer, B ;
Lloid, ME ;
Potter, JD ;
Ulrich, CM .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1268-1275
[9]
Ruescher TJ, 1998, CANCER-AM CANCER SOC, V82, P2275, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2275::AID-CNCR25>3.0.CO
[10]
2-Q